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Abstract  26 
Alkaptonuria is an inherited disease caused by homogentisate 1,2-dioxygenase (HGD) 27 
deficiency. Circulating homogentisic acid (HGA) is elevated and deposits in connective 28 
tissues as ochronotic pigment. In this study, we aimed to define developmental and adult 29 
HGD tissue expression and determine the location and amount of gene activity required to 30 
lower circulating HGA and rescue the alkaptonuria phenotype.  31 
 32 
We generated an alkaptonuria mouse model using a knockout-first design for the disruption 33 
of the HGD gene. Hgd tm1a -/- mice showed elevated HGA and ochronosis in adulthood. 34 
LacZ staining driven by the endogenous HGD promoter was localised to only liver 35 
parenchymal cells and kidney proximal tubules in adulthood, commencing at E12.5 and 36 
E15.5 respectively. Following removal of the gene trap cassette to obtain a normal mouse 37 
with a floxed 6th HGD exon, a double transgenic was then created with Mx1-Cre which 38 
conditionally deleted HGD in liver in a dose dependent manner. 20% of HGD mRNA 39 
remaining in liver did not rescue the disease, suggesting that we need more than 20% of liver 40 
HGD to correct the disease in gene therapy.  41 
 42 
Kidney HGD activity which remained intact reduced urinary HGA, most likely by increased 43 
absorption, but did not reduce plasma HGA nor did it prevent ochronosis. In addition, 44 
downstream metabolites of exogenous 13C6-HGA, were detected in heterozygous plasma, 45 
revealing that hepatocytes take up and metabolise HGA.  46 
 47 
This novel alkaptonuria mouse model demonstrated the importance of targeting liver for 48 
therapeutic intervention, supported by our observation that hepatocytes take up and 49 
metabolise HGA. 50 
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Introduction 51 
Alkaptonuria (AKU; OMIM #203500) is a rare metabolic recessive disease where the 52 
enzyme homogentisate 1,2-dioxygenase (HGD; EC 1.13.11.5), that is mainly found in the 53 
liver, is deficient (1). Garrod in 1908 unveiled the term inborn error of metabolism and 54 
proposed that AKU was caused by the lack of an enzyme that in normal individuals split the 55 
aromatic ring of homogentisic acid (HGA) (2). Biochemical evidence of the defect in AKU 56 
was provided by La Du in 1958, where he demonstrated the absence of HGD activity in a 57 
liver homogenate prepared from an AKU patient and established that the failure to synthesize 58 
active enzyme was the sole cause of AKU (1).  59 
 60 
HGD deficiency leads to HGA accumulation in the blood and tissues, despite urinary 61 
excretion. It has been proposed that excess HGA undergoes oxidation and polymerization to 62 
form a dark brown ochronotic pigment (3) that deposits in connective tissues such as the skin, 63 
sclera, spine and articular cartilage, as well as in heart valves (4, 5), where it causes aortic 64 
stenosis (6). AKU patients suffer from early-onset severe osteoarthropathy due to premature 65 
degeneration of articular cartilage and disease manifestations worsen with age. Despite liver 66 
deficiency of HGD, the main pathophysiological manifestation of AKU relates to the 67 
function of non-metabolised HGA in the joints.   68 
 69 
HGD has been mapped onto human chromosome 3q13.33 70 
(http://www.ncbi.nlm.nih.gov/gene/3081) (7, 8). Currently, 203 different HGD pathogenic 71 
variants have been identified (HGD mutation database: http://hgddatabase.cvtisr.sk) (9, 10), 72 
of which the most frequent are missense variants (representing 68.3%), followed by splicing 73 
(13.4%) and frameshift (11.3%) mutations (11). In addition to the liver, HGD is thought to be 74 
expressed in the prostate, small intestine, colon, and kidney (12), as well as in osteoarticular 75 
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compartment cells (chondrocytes, synoviocytes, and osteoblasts) (13), and the brain (14). 76 
However, this has not been verified by in-situ hybridisation or HGD labelling. 77 
 78 
Currently, AKU treatment is palliative via analgesics and joint replacement, with dietary 79 
protein restriction and vitamin C showing little or no efficacy (15). Recently there have been 80 
trials of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), more 81 
commonly referred to as nitisinone, in the treatment of AKU (16). Nitisinone, which inhibits 82 
the HGA producing enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD; EC 1.13.11.27), 83 
has been  the licensed treatment for hereditary tyrosinaemia type 1 (HT-1; OMIM #276700) 84 
since 2002, where fumarylacetoacetate hydroxylase (FAH; EC 3.7.1.2) deficiency results in 85 
liver failure, hepatocellular carcinoma and renal tubular dysfunction (17). Moreover, the off-86 
licence use of nitisinone at the National Alkaptonuria Centre (Liverpool, UK) has shown a 87 
decreased rate of disease progression in addition to lowering serum and urine HGA (18).  88 
 89 
Treatment of other inborn errors of metabolism related to the phenylalanine/tyrosine pathway 90 
by enzyme replacement has been attempted with some success (19). In the past decade, liver-91 
directed gene therapy has emerged as a promising alternative to transplantation in monogenic 92 
liver disorders such as AKU (20). The level of HGD required to rescue the disease, if 93 
expression outside the liver can affect the phenotype and whether circulating HGA can be 94 
metabolised by HGD-expressing cells are essential questions that must be addressed before 95 
such treatments are investigated. 96 
 97 
To answer these questions, a new targeted knockout-first AKU mouse model was generated. 98 
This mouse harbours a LacZ reporter gene within the HGD locus for localising gene 99 
expression and was conditionally manipulated to obtain an inducible and liver-specific 100 
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knockout. This study provides compelling evidence that targeting hepatic HGD plays an 101 
indispensable role in any enzyme replacement or gene therapy for AKU.  102 
 103 
Results 104 
Generation of the conditionally targeted Hgd mouse 105 
ES cells from clone C10 resulted in chimeras which achieved germline transmission. This 106 
knockout-first allele (Hgd tm1a) contained an IRES:LacZ gene trap cassette and a promoter-107 
driven neo cassette inserted into the fifth HGD intron with the sixth exon flanked by loxP 108 
sequences, see figure 1A (21, 22). Homozygous Hgd tm1a mice showed an AKU phenotype 109 
due to HGD gene disruption. In C10/tm1a mice, Lox-F/Hgd-R primers amplified the loxP 110 
sequence (257bp) showing the allele was floxed (figure 1). Hgd-F/Hgd-ttR primers produced 111 
a 561bp band in the wildtype allele; the gene trap cassette sequence in the modified allele was 112 
too large to be amplified. Homozygous tm1a therefore had only the 257bp floxed band, 113 
heterozygotes had both the floxed 257bp and wildtype 561bp bands and wildtype had only 114 
the 561bp band (figure 1B). 115 
 116 
Hgd tm1c had restored HGD gene expression due to removal of the gene trap and was 117 
phenotypically wildtype. To achieve inducible and conditional HGD deletion, interferon 118 
inducible Mx-1 was used to drive expression of cre recombinase, MxCre (23), generating the 119 
Hgd tm1d allele. In the post-flp tm1c and tm1d (before cre recombination), Lox-F/Hgd-R 120 
primers showed the allele was floxed (257bp) and Hgd-F/Hgd-ttR primers showed that Flp 121 
recombination had occurred (673bp). Wildtype tm1c/d had only the 561bp band (Hgd-F/Hgd-122 
ttR). Homozygous tm1c/d had both the 257bp floxed and 673bp post-flp bands and 123 
heterozygous tm1c/d had all three bands (257bp floxed, 673bp post-flp and 561bp wildtype), 124 
see figure 1C. Primers produced a band at 520bp when MxCre was present (figure 1D). 125 
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 126 
Elevation of HGA in plasma and urine 127 
HGA was measured in urine and plasma of mice (figure 1E-F). Urinary HGA (mean ±SEM) 128 
was elevated approximately 100,000-fold (99,575 ±30,851µmol/L) and plasma HGA 129 
elevated about 100-fold (100.5 ±34.9µmol/L) in the Hgd tm1a -/- mice compared to Hgd 130 
tm1a -/+ (plasma: 2.0 ±0.5µmol/L; urine: 15 ±25.3µmol/L), Hgd tm1c (plasma: 2.0 131 
±1.0µmol/L; urine: 2.4 ±2.9µmol/L) and C57BL/6 wildtype (plasma: 1.7 ±0.6µmol/L; urine: 132 
0.8 ±0.2µmol/L) mice. These differences were all statistically significant (p<0.001; one-way 133 
ANOVA, Tukey-Kramer post-hoc).  134 
 135 
As AKU is present at birth, plasma HGA was measured in day 1 Hgd tm1a -/- pups (2 pools 136 
of n=3; gestation: 19.5 days), see figure 1G. Plasma HGA (mean ±SEM) was elevated 3-fold 137 
in day 1 pups (308.8 ±18.9µmol/L) compared with adult Hgd tm1a -/- mice (100.5 138 
±8.7µmol/L).  139 
 140 
Detection of ochronosis and its progression 141 
Knee joints from Hgd tm1a -/- mice aged 7–40 weeks were examined for pigmentation. 142 
Ochronosis was found in calcified articular cartilage (figure 2A), first appearing at 9 weeks 143 
(figure 2B). The pigment was initially pericellular (9-11 weeks) and very infrequent. At 26 144 
and 40 weeks (figure 2C and 2E respectively), the number and intensity of pigmented 145 
chondrons were increased and showed advancement to the intracellular compartment. 146 
Clusters of pigmented chondrons were seen at ligament attachment sites (not shown). At 40 147 
weeks, pigmentation was still confined to calcified cartilage. Heterozygous controls showed 148 
no pigmentation at 26 and 40 weeks (figure 2D and 2F respectively).   149 
 150 
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Adult HGD expression 151 
Adult tissues from Hgd tm1a -/- were stained for LacZ to visualise HGD expression as blue 152 
staining. Positive staining was present in the liver and kidney cortex after 2 hours which 153 
intensified when left overnight (figure 3A). Heterozygous staining was less intense (not 154 
shown) and was slower to develop. Hgd tm1c wildtype-like liver and kidney did not stain 155 
(figure 3A). All other Hgd tm1a tissues investigated including brain, heart, lung, muscle, 156 
spleen, intestine, skin, bone, cartilage, eye and prostate were negative. HGD mRNA analysis 157 
via qPCR (HGD1 primers spanning exons 3-4 before gene trap cassette) confirmed this 158 
staining pattern, with HGD expression only present in liver and kidney (figure 3B). 159 
 160 
LacZ in whole liver and kidney was limited by the penetration of substrate therefore frozen 161 
section staining was undertaken to demonstrate that LacZ and therefore HGD is expressed in 162 
the cytoplasm throughout the liver parenchyma (figure 3C). In the kidney cortex, glomeruli 163 
were LacZ negative, and only certain tubules stained positive (figure 3D), which were 164 
identified using periodic acid schiff for brush border staining in proximal convoluted tubules 165 
(PCT) (figure 3E,F).  166 
 167 
Embryonic HGD expression 168 
To determine when HGD is expressed, LacZ staining of time-mated Hgd tm1a -/- embryos 169 
was carried out. Whole embryo staining showed positive LacZ staining in the liver at E14.5 170 
and onwards (figure 3G). However, histological sections revealed punctate staining at E12.5 171 
and onwards in the liver (figure 3H). Positive LacZ staining was seen in the kidney at E15.5 172 
in some of the developing kidney tubules (figure 3H). All other embryonic tissues examined 173 
in frozen sections, including brain, eye, bones and other internal organs were LacZ negative. 174 
 175 
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Similarly, liver HGD mRNA expression in Hgd tm1a -/- (HGD1 primers spanning exons 3–4 176 
before gene trap cassette) was analysed by qPCR (figure 3I) at E12.5 (n=3), E13.5 (n=3), 177 
E14.5 (n=4) and E15.5 (n=3), day 1 pups (n=6) and compared with adult mice (n=4, male, 178 
mean age 19.7 weeks). Compared to the adult, liver HGD expression was 0.3% at E12.5, 179 
0.8% at both E13.5 and E14.5, and 2.3% at E15.5. This considerable difference in HGD 180 
mRNA was reflected in the LacZ staining intensity seen between the adult liver (figure 3C) 181 
compared to the embryo liver (figure 3H). Day 1 pup liver HGD expression was 12.6% of the 182 
adult expression level (8-fold lower). 183 
 184 
Inducible and liver-specific HGD knockout 185 
To investigate the effect of liver-specific HGD gene deletion, double transgenic Hgd tm1d 186 
MxCre +ve mice (n=5) and wildtype (n=3) and AKU (n=4) controls were injected with pIpC. 187 
Blood and urine samples were collected according to the scheme in figure 4A. 15 days after 188 
the first pIpC injection, MxCre +ve mice showed a 77.6% decrease in liver HGD mRNA 189 
compared with wildtype controls (figure 4B). Kidney HGD expression in MxCre +ve mice 190 
did not change and was comparable to wildtype controls (figure 4C). AKU mice had no HGD 191 
mRNA expression as expected (primers span exons 9–10 after gene trap cassette).  192 
 193 
Following the knockout of approximately 78% liver HGD mRNA in MxCre +ve mice, mean 194 
plasma HGA (±SEM) increased from 0.2 ±0.2µmol/L to 129.3 ±35.6µmol/L at 15 days post-195 
pIpC (figure 4D). MxCre +ve urinary HGA (figure 4E) was elevated from 9.4 ±7.1µmol/L to 196 
11,807 ±974µmol/L at 15 days post-pIpC but remained low in comparison to AKU controls 197 
(134,948 ±18,479µmol/L). Both plasma and urinary HGA remained high in AKU controls 198 
and low in wildtype controls as expected. 199 
 200 
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Long-term liver-specific HGD knockout  201 
MxCre +ve mice (n=15) and AKU controls (n=5) were injected with pIpC. MxCre +ve 202 
wildtype controls were injected with PBS (n=5) as wildtype controls. Injections and sampling 203 
of blood and urine was carried out according to the scheme in figure 5A. MxCre +ve mice 204 
injected with pIpC were culled at 9 (n=5), 15 (n=5) and 20 (n=5) weeks post-injection, with 205 
wildtype and AKU controls culled at 20 weeks. Liver and kidney mRNA was taken and knee 206 
joints were taken to assess ochronosis. 207 
 208 
As with the previous study, liver HGD mRNA was reduced in pIpC-injected MxCre +ve 209 
mice, which was sustained to 20 weeks post-injection, see figure 5B. Compared to wildtype 210 
controls, liver HGD expression was 11.7%, 17.7% and 18.4% at 9, 15 and 20 weeks 211 
respectively. Kidney HGD expression in the MxCre +ve mice remained comparable to 212 
wildtype controls (figure 5C). The reduction of liver HGD mRNA in the MxCre +ve mice 213 
subsequently caused plasma HGA to increase (figure 5D) to a level comparable with AKU 214 
controls. Urinary HGA (figure 5E) was increased in the MxCre +ve mice but not to that of 215 
AKU controls. Knee sections stained with Schmorls’ stain were scored to obtain the number 216 
of pigmented chondrons found in a representative knee joint section (figure 5F). Few or no 217 
pigmented chondrons were found in the MxCre +ve knee joints 9 weeks post-pIpC, 218 
increasing in number at 15 and 20 weeks. Wildtype controls showed no pigmentation.  219 
 220 
Liver-specific HGD knockout: dose response 221 
In order to investigate the effect of varying liver HGD mRNA expression levels on the AKU 222 
phenotype, a short term dose response study was carried out. Figure 6A demonstrates the 223 
study design. MxCre +ve mice were given two injections of pIpC at the following doses; 224 
3.33µg/g (n=3), 1µg/g (n=3), 0.33µg/g (n=3), 0.1µg/g (n=5), 0.03µg/g (n=3) and 0.01µg/g 225 
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(n=3) body weight. AKU (Hgd tm1a -/-; n=4) and wildtype (MxCre WT; n=7) controls were 226 
given the highest dose of 3.33µg/g pIpC. With the exception of the 0.01µg/g group, liver 227 
HGD mRNA in MxCre +ve mice was reduced at 15 days post-injection (figure 6B) in all 228 
groups, with a dose response observed at the lower pIpC doses. The mean liver HGD 229 
expression in MxCre +ve mice 15 days post-pIpC compared to wildtype controls was 230 
lowered to 17.0%, 20.5%, 20.5%, 53.4% and 54.5% with decreasing pIpC doses from 231 
3.33µg/g – 0.03µg/g. The mean liver HGD expression in the 0.01µg/g group was comparable 232 
to the WT controls. Kidney HGD expression was unchanged (figure 6C). 233 
 234 
Plasma HGA in MxCre +ve mice at 15 days post-pIpC were lowered in a dose responsive 235 
manner (mean ±SEM) to 75.0 ±20.9, 57.9 ±20.9, 27.2 ±9.6, 22.7 ±13.4, 26.1 ±24.1 and 1.3 236 
±0.4 µmol/L with decreasing pIpC doses (figure 6D). Similarly, urine HGA demonstrated a 237 
dose response at 15 days post-pIpC, at (mean ±SEM) 45,074 ±14,977, 14,169 ±13,783, 6,137 238 
±6,064, 5,717 ±5,667, 31,043 ±31,041 and 2.0 ±0.2 µmol/L with decreasing pIpC doses 239 
(figure 6E). These levels of urine HGA were elevated compared with wildtype (1.9 ±0.2 240 
µmol/L) controls, but lower than AKU (113,067 ±10,609 µmol/L) controls. Figure 6F-G 241 
show the relationship between liver HGD mRNA (expressed as percentage of the mean 242 
wildtype level) and HGA.  243 
 244 
Metabolism of circulating HGA 245 
To determine if circulating HGA can be taken up by HGD-expressing cells to be metabolised 246 
intracellularly, both Hgd tm1a -/- (n=4) and Hgd tm1a -/+ (n=4) mice were injected with 247 
13C6-HGA into the tail vein. Plasma samples were then collected at various time points, from 248 
2–60 minutes post-injection. HGA in its native form (m+0) was detected in plasma of Hgd 249 
tm1a -/- mice at all time points, and was absent in Hgd tm1a -/+ mice (not shown). 13C6-HGA 250 
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was detected in both Hgd tm1a -/- and -/+ mice after injection (figure 7). M+6 isotopologues 251 
of fumarylacetoacetic acid (13C6-FAA)/maleylacetoacetic acid (
13C6-MAA), 
13C6-labelled 252 
downstream metabolites, were detected in Hgd tm1a -/+ mice after 13C6-HGA injection, and 253 
were not detected in Hgd tm1a -/- mice. Native FAA/MAA was not detected in either Hgd 254 
tm1a -/- or -/+ mice (not shown). 255 
 256 
Discussion 257 
Management of inborn errors of metabolism such as AKU has traditionally consisted of diet 258 
and supportive therapy. However, other treatment options have become available, including 259 
enzyme inhibition (17, 24), enzyme replacement (19), cell and organ transplantation (20), 260 
gene therapy (20) and CRISPR technology (25).  261 
 262 
The pathophysiology of AKU has been investigated in ex vivo tissue samples (14, 26, 27) and 263 
in vitro models (13, 28) but to investigate the metabolic consequences of AKU and novel 264 
therapeutic approaches, we have generated a well-characterised animal model. This model 265 
will be used to investigate all aspects of AKU pathophysiology including the mechanism of 266 
ochronosis and any associated tissue changes including amyloidosis (29). We have generated 267 
a HGD knockout-first mouse model that included a beta galactosidase (LacZ) gene trap 268 
within the HGD gene locus, that has enabled precise localistation of HGD expression. 269 
Targeted gene disruption in Hgd tm1a removes any potentially confounding mutations that 270 
could be present in an existing ENU (N-ethyl-N-nitrosourea) AKU mouse model (30), as 271 
ENU mutagenesis causes a high frequency of genomic mutations (31). This new mouse 272 
recapitulated the human disease. Manipulation of this Hgd tm1a knockout-first allele by 273 
FRT/flp and Cre/loxP recombination enabled liver-specifc HGD deletion in double transgenic 274 
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Hgd tm1d MxCre +ve mice, highlighting important considerations for future therapy in 275 
AKU. 276 
 277 
Plasma HGA in Hgd tm1a -/- is comparable to that previously reported values in the ENU 278 
AKU mouse (30). This mutagenesis model exhibited the first signs of ochronosis at 15 weeks 279 
(30). Knee joints were therefore examined from 7-11 weeks in Hgd tm1a -/- mice, with 280 
pericellular pigmentation identified at 9 weeks; progression was then similar to mutagenesis 281 
AKU mice. Ochronosis in the mouse appears to represent the early stages of human joint 282 
pathophysiology in AKU with pigmentation confined to individual chondrocytes and their 283 
territorial matrix in the calcified cartilage. 284 
 285 
The LacZ reporter gene has enabled both temporal and spatial histological localisation of 286 
HGD showing that HGD was expressed throughout the liver parenchyma and kidney PCT 287 
cells. It has previously been suggested that HGD is expressed in the intestine and prostate 288 
(12), brain (14) and bone/cartilage (13), but this was not evident using this knock-in LacZ 289 
reporter gene, nor by qPCR analysis of HGD mRNA.  290 
 291 
LacZ staining of time-mated embryos demonstrated that hepatic HGD expression begins at 292 
E12.5 (figure 3H), confirmed with qPCR analysis of liver HGD mRNA from E12.5-E15.5. 293 
Hepatic cords, containing hepatoblasts, have formed by E10.0 in the developing liver 294 
alongside haematopoietic cells. The liver then expands due to hepatoblast proliferation and 295 
haematopoietic activity from E10.5-E11.5 (32). Haematopoietic activity rapidly increases, 296 
peaking at E13.5 and does not start to decline until E15.5 (32). Haematopoietic cells 297 
encompass almost 75% of total liver volume at E13.0 (33) with hepatoblasts at E13.5 having 298 
limited contact with each other (32), explaining the diffuse and punctate LacZ staining and 299 
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low HGD mRNA level in the embryonic liver. Murine hepatoblasts begin to differentiate into 300 
hepatocytes at E14.5 (32). Haemaotpoietic activity continues into the first post-natal week, 301 
which may explain why day 1 pups have about an eighth of adult HGD expression (32). In 302 
the kidney, adult LacZ staining suggests that the LacZ positive cells seen at E15.5 are 303 
developing PCT cells of the nephron.  304 
 305 
HGD expression begins in embryonic development. The 3-fold greater HGA level seen at 306 
birth compared to adulthood in Hgd tm1a -/- mice (figure 1G) highlights the importance of 307 
HGD, even at this very early time point, perhaps suggesting that therapeutics strategies, such 308 
as nitisinone (16) or gene/enzyme replacement should ideally begin in early life or at birth. 309 
 310 
Liver-specific HGD deletion 311 
To investigate contribution of non-hepatic HGD towards HGA metabolism, double 312 
transgenic mice were generated by mating floxed Hgd tm1d mice with an MxCre 313 
recombinase line, and used for liver-specific HGD deletion (23, 34). Two doses of 10µg/g 314 
body weight pIpC (figure 4,5) resulted in an approximate 80% reduction in liver HGD 315 
mRNA, whilst kidney HGD mRNA was maintained at the wildtype level. This reduction of 316 
liver HGD mRNA and subsequent increase in plasma HGA to a level comparable with AKU 317 
controls suggests that hepatic HGD is crucial for HGA metabolism. 318 
 319 
These results indicate that future gene/enzyme replacement therapy should target the liver to 320 
combat elevated plasma HGA that causes ochronosis in AKU. This is supported by a case 321 
report of an AKU patient receiving a liver transplant, after which they found no HGA in the 322 
urine and reported a halt in progressive arthropathy (35). Full liver HGD mRNA knockout 323 
was not achieved with two 10µg/g doses in the present study. Further reducing liver HGD 324 
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mRNA, would not provide further insight into the level of liver HGD mRNA required to 325 
rescue the phenotype.  326 
 327 
The data here reveals that approximately 20% liver HGD mRNA, delivered by gene therapy 328 
for example, will not rescue AKU; elevated HGA subsequently caused ochronosis in the knee 329 
joints of the mice (figure 5F). Determining how much liver HGD is required to rescue the 330 
phenotype is an important question for future therapy. The dose response study here (figure 331 
6) intended to estimate how much liver HGD mRNA would significantly lower circulating 332 
HGA. A dose response was observed in both the plasma and urine HGA levels (figure 6D,E). 333 
However, for liver HGD mRNA, there was only a dose response between 0.33-0.01µg/g 334 
pIpC. One possible explanation for HGD mRNA not corresponding to plasma HGA in the 335 
other dose groups could be that the mRNA:protein ratio is not linear. Thus we suggest that 336 
the minimum level of liver HGD mRNA required to eliminate circulating HGA must fall 337 
between the dashed lines (figure 6F), between 26% and 43% of liver HGD mRNA. 338 
 339 
The intact kidney HGD mRNA did not have an impact on plasma HGA, but instead caused 340 
reduced urinary HGA compared to AKU controls. In 2002, an AKU patient who received a 341 
kidney transplant reportedly had normalised plasma HGA and decreased urinary HGA (both 342 
approximately half pre-transplant levels) (36). Liver-specific HGD deletion shown here in 343 
mice however suggests that kidney HGD mRNA is unlikely to rescue the AKU phenotype as 344 
blood HGA levels were elevated. The improvement reported with kidney transplantation was 345 
likely due to improved renal elimination as the patient had renal failure and subsequently 346 
very high HGA pre-transplant, rather than donor HGD expression. Indeed, in the conditional 347 
mouse model (figures 4-5) we were expecting high HGA in the urine when circulating HGA 348 
increased. However, in the liver-specific knockout, the urine level did not increase, 349 
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suggesting HGA reabsorption and subsequent metabolism by the intact kidney HGD, for 350 
which we do not know the mechanism. Fundamentally, the importance of this finding is that 351 
intact kidney HGD does not rescue the disease and therefore liver HGD is critical for the 352 
correction of AKU. 353 
 354 
HGD activity and HGA metabolism: considerations for gene therapy 355 
Restoring HGD activity in all liver cells, via gene therapy or enzyme replacement, is 356 
unachievable by any current method, but the data here suggests that it is not necessary. In 357 
heterozygous mice and humans, one functioning copy of the HGD gene in all cells is 358 
sufficient to deal with HGA metabolism. Assuming heterozygous mice possess 50% of the 359 
HGD mRNA compared with wildtypes (adult LacZ staining suggests this assumption is 360 
correct), then 50% HGD mRNA in every hepatocyte can rescue AKU. As described above, 361 
conditional deletion to 20% of total HGD liver mRNA, did not appear to rescue the 362 
phenotype. However, we cannot determine how many cells were expressing the gene, either 363 
as one or two alleles, nor the distribution of expression which could be variable from cell to 364 
cell. The proportion of corrected cells and the level of therapeutic gene expression per cell 365 
required to rescue AKU is therefore still not clear. A recent study providing the first human 366 
genotype-phenotype correlation data for the three most frequent HGD mutation variants (33 367 
patients homozygous for these variants) identified in the SONIA-2 trial demonstrated no 368 
difference in baseline visit serum or 24-hour urine HGA, or clinical symptoms such as eye 369 
pigmentation, hip bone density or degree of scoliosis between patients predicted to have 1% 370 
(16 patients) or 31%-34% (17 patients) residual HGD catalytic activity  as determined in vitro 371 
against wildtype recombinant human HGD enzyme) (9). 372 
 373 
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Another consideration for gene therapy is that hepatocytes without sufficient HGD activity to 374 
metabolise HGA could lead to its accumulation in the bloodstream. In this study, intravenous 375 
injection of isotopically labelled HGA (figure 7) provides evidence that circulating HGA can 376 
re-enter HGD-expressing cells to be metabolised by intracellular HGD. Thus, it should not be 377 
necessary to repair 100% of liver cells because HGA produced by AKU hepatocytes could be 378 
taken up and metabolised by genetically repaired cells. This model represents a paradigm for 379 
inherited liver metabolic diseases, in particular, genetic disorders of tyrosine metabolism. 380 
 381 
Conclusion 382 
In summary, this new targeted HGD knockout mouse exhibits the characteristic traits of 383 
AKU. Both adult and embryo HGD expression has been localised to only liver and kidney 384 
using a reporter gene within the HGD locus. More importantly, the conditional Hgd tm1d 385 
MxCre model has highlighted the importance of liver HGD expression in limiting the 386 
pathological effects of the HGA pool despite apparent reabsorption of HGA in the kidney. 387 
 388 
Materials and Methods 389 
Generation of HGD knockout-first mice 390 
Two ES cell lines (clones Hgd C10, Hgd C11) were obtained from the UC Davis KOMP 391 
repository. They were grown on feeder cells as described (37). Healthy ES colonies were 392 
injected into blastocysts of C57BL/6 (Harlan, UK) and chimeras born from both lines. Only 393 
C10 chimeras achieved germline transmission. All mice were housed and maintained within 394 
the University of Liverpool Biological Services Unit in specific pathogen-free conditions in 395 
accordance with UK Home Office guidelines. Food and water were available ad libitum.  396 
 397 
Urine and Blood Collection 398 
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Tyrosine pathway metabolites in acidified urine and plasma from venous tail bleeds were 399 
analysed via high performance liquid chromatography (HPLC) tandem mass spectrometry 400 
assays (38, 39).  401 
 402 
LacZ staining; tissues/embryos 403 
Embryos from E13.5 to E16.5 were stained for ß-galactosidase as previously described (40). 404 
Adult tissues were stained via the same protocol with size-adjusted fixation times. 405 
 406 
LacZ staining; frozen sections 407 
Frozen liver and kidney sections (6µM) were fixed (0.2% glutaraldehyde in PBS) for 10 408 
minutes. After three washes in cold PBS they were stained for ß-galactosidase as above and 409 
counterstained with eosin. Whole embryos were fixed as above, transferred to 30% sucrose 410 
overnight and then embedded in OCT on dry ice. Frozen sections (7µM) were LacZ stained 411 
at room temperature overnight. 412 
 413 
qPCR 414 
RNA was extracted using the Qiagen RNeasy Mini Kit, reverse transcription of RNA was 415 
carried out using the Applied Biosystems RNA-to-cDNA kit and qPCR was performed using 416 
the Bio-Rad iQ™ SYBR® Green Supermix. HGD1 primers; forward 5’- 417 
TGTCCACGGAACACCAATAA-3’ and reverse 5’- GCCAACTTCATCCCAGTTGT-3’. 418 
HGD2 primers; forward 5’-GACCCATCGGAGCAAATGGC-3’ and reverse 5’-419 
AGTGTAACCACCTGGCACTC-3’. 18S (housekeeping gene) primer sequences; forward 420 
5’-TGTCCACGGAACACCAATAA-3’ and reverse 5’-AGTTCTCCAGCCCTCTTGGT-3’.  421 
18S was not affected by pIpC administration. 422 
 423 
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Ochronosis 424 
Coronal knee joint paraffin sections were Schmorl’s stained and counterstained with nuclear 425 
fast red (28, 41) to identify pigmented chondrons. Scoring of all four joint quadrants was 426 
carried out blind to experimental conditions and genotype. 427 
 428 
Hgd tm1d conditional knockout 429 
To obtain the conditional Hgd tm1d line, Hgd tm1a mice were crossed with Flpo mice to 430 
remove the FRT-flanked gene trap cassette, leaving a floxed target exon (Hgd tm1c) (42). 431 
Homozygote floxed Hgd tm1c mice were crossed with MxCre mice. The removal of the 432 
floxed 6th exon was induced with two intraperitoneal injections of polyinosinic:polycytidylic 433 
acid (pIpC) at 10µg/g body weight (43). Hgd tm1a -/- mice were injected with pIpC as AKU 434 
controls and wildtype controls were either Hgd tm1d MxCre WT injected with pIpC or Hgd 435 
tm1d MxCre +ve mice with PBS. HGA was measured in plasma and urine samples collected 436 
pre-injection and at time points post-injection. Liver and kidney HGD mRNA was analysed. 437 
In the long-term study, knee joints were collected for ochronosis scoring. For the dose 438 
response study, the same protocol was followed as above, using diluted pIpC at doses 439 
3.33µg/g to 0.01µg/g body weight. 440 
 441 
Isotopic HGA injection 442 
Hgd tm1a -/- (n=4) and Hgd tm1a -/+ (n=4) mice were injected with 13C6-HGA into the 443 
lateral tail vein, adjusted to body weight to achieve a final blood concentration of 444 
approximately 1mmol/L. Under anaesthesia, venous tail bleeds were collected at time points 445 
post-injection, ranging from 2-60 minutes. Whole blood was centrifuged and the supernatant 446 
removed and immediately frozen.  447 
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Non-targeted metabolic flux analysis was performed to trace metabolism of 13C6-HGA. 448 
Metabolic profiling was performed using a published mass spectrometric technique (44). 449 
Briefly, plasma was diluted 1:9 plasma:deionised water and HPLC performed on an Atlantis 450 
dC18 column (3x100mm, 3µm, Waters, UK) coupled to an Agilent (Cheadle, UK) 6550 451 
quadrupole time-of-flight mass spectrometer. An accurate-mass compound database with 452 
potential association to HGA was generated for data mining using Agilent Pathways to 453 
PCDL. Data were mined for these compound targets with an accurate mass window of 454 
±5ppm using ‘batch isotopologue extraction’ in Profinder (build 08:00, Agilent). 455 
Isotopologue extraction investigates association with the injected 13C6-HGA by examining 456 
the relative abundances of the M+0 – M+6 isotopologues for compound targets. 457 
 458 
Statistical analysis 459 
Statistical analysis was performed using Stats Direct 3 statistical software (UK). Significance 460 
is denoted as p<0.05 *, p<0.01 ** and p<0.001 ***.  461 
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Figures and Legends 630 
 631 
Figure 1. Phenotyping of Hgd tm1a mice. A-D shows genotyping of the modified HGD 632 
allele. A schematic of the modified HGD allele is shown in A. Hgd tm1a: AKU phenotype. 633 
Hgd tm1c: wildtype phenotype. Hgd tm1d: liver-specific and inducible KO. Using primer 634 
pairs Hgd-F/Hgd-ttR and Lox-F/Hgd-R, B shows the genotyping of tm1a; C shows the 635 
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genotyping of tm1c (after flp recombination) and tm1d (before cre recombination). D shows 636 
the genotyping of MxCre. A 2-log DNA ladder was used in B-D. E-H show elevation of 637 
HGA in Hgd tm1a -/-. E and F show plasma and urine HGA. Plasma HGA is elevated 638 
approximately 100-fold in Hgd tm1a -/- mice (n=16) compared to C57BL/6 wildtype (n=4), 639 
Hgd tm1c +/+ (n=7) and Hgd tm1a -/+ (n=18) controls. Urinary HGA is elevated 640 
approximately 10,000-100,000-fold in Hgd tm1a -/- mice (n=19) compared with C57BL/6 641 
wildtype (n=7), Hgd tm1c +/+ (n=7) and Hgd tm1a -/+ (n=19) controls. G shows HGA levels 642 
in day 1 Hgd tm1a -/- pups (2 pools of n=3) compared with adults (n=16). HGA = 643 
homogentisic acid. Significance: p<0.05 *, p<0.01 ** and p<0.001 ***. Error bars represent 644 
SEM. 645 
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 646 
Figure 2. Initiation and progression of ochronosis in Hgd tm1a mice. H+E staining in A 647 
shows division of articular cartilage into different zones: hyaline cartilage (HC) and calcified 648 
articular cartilage (CAC) separated by the tidemark (T). Deep to calcified articular cartilage is 649 
subchondral bone (SB). B–F show femoral condyles from Hgd tm1a mice that have been 650 
Schmorl’s stained (stains ochronotic pigment a blue colour). B shows pericellular 651 
pigmentation of chondrons situated in the calcified articular cartilage in a 9 week Hgd tm1a -652 
/- femoral condyle. C and E show the femoral condyle of Hgd tm1a -/- mice at 26 and 40 653 
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weeks respectively. The pigmentation has advanced to the inner compartment of the cell, 654 
with more numerous affected chondrocytes showing varying pigment intensities. The 655 
pigmentation is still confined to the calcified articular cartilage layer. Hgd tm1a -/+ mice at 656 
26 and 40 weeks (D and F respectively) show no pigmentation. All sections: 6µM. 657 
 658 
 659 
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 660 
Figure 3. Localisation of HGD expression. A shows LacZ staining in adult liver (top row) 661 
and kidney (bottom row). LacZ blue staining blue represents HGD expression seen only in 662 
the liver parenchyma and kidney cortex of Hgd tm1a -/- adult mice. Control Hgd tm1c +/+ 663 
liver and kidney were LacZ negative. B shows HGD mRNA across a variety of adult Hgd 664 
tm1d WT tissues analysed via qPCR (HGD1 primers). C-F shows frozen section staining of 665 
adult liver and kidney from Hgd tm1a -/- mice, with liver (C) and kidney cortex (D) showing 666 
Accepted 07/09/2019; Human Molecular Genetics; Author Version 
32 
 
specific LacZ staining after 2 hours. In E, PAS staining distinguishes PCTs from DCTs by 667 
the presence of a PAS-positive dark pink/purple brush border. In F, the LacZ blue cells 668 
localise with the PAS-positive PCT cells. G-I shows HGD expression in Hgd tm1a -/- 669 
embryos. G shows whole time-mated embryo LacZ staining, with positive staining seen at 670 
E14.5 in the liver. H shows microscopic frozen section LacZ staining of liver and kidney. 671 
Positive staining is seen at E12.5 onwards in liver and from E15.5 in kidney. I shows HGD 672 
mRNA (HGD1 primers) in E12.5 (n=3), E13.5 (n=3), E14.5 (n=4) and E15.5 (n=3) embryos, 673 
day 1 pups (P1) (n=6) and adult Hgd tm1a -/- mice (n=4). All sections: 6/7µM. PAS: Periodic 674 
acid Schiff. PCT = proximal convoluted tubule. DCT: distal convoluted tubule. Error bars 675 
represent SEM. HGD expression normalised to 18S. 676 
 677 
 678 
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 679 
Figure 4. Liver-specific HGD knockout, induced by pIpC injection, in Hgd tm1d MxCre +ve 680 
mice. A, shows the timescale of blood and urine sampling and pIpC injections. B and C show 681 
HGD mRNA (HGD2 primers; relative to 18S) in Hgd tm1a -/- (AKU controls, n=4), Hgd 682 
tm1d MxCre WT (wildtype controls, n=3) and Hgd tm1d MxCre +ve mice (MxCre +ve, n=5) 683 
in the liver and kidney respectively, 15 days after pIpC injection. MxCre +ve mice show 684 
reduced liver, but not kidney, HGD expression compared to wildtype controls. D and E show 685 
plasma and urine HGA, respectively, pre-injection, 9 and 15 days after pIpC injection. Pre-686 
injection, HGA in the plasma is not detected in MxCre +ve or WT mice. Hgd tm1a -/- mice 687 
show high HGA. Post-pIpC, plasma HGA in MxCre +ve mice is increased. Pre-injection, 688 
urinary HGA is low in MxCre +ve and WT mice compared to Hgd tm1a -/-. Post-pIpC, 689 
urinary HGA shows a relatively small increase in MxCre +ve mice.   690 
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 691 
Figure 5. Long-term follow up of Hgd tm1d MxCre +ve mice injected with pIpC. A shows 692 
the timescale of blood and urine sampling and pIpC injections. Hgd tm1a -/- were injected 693 
with pIpC (AKU controls, n=5). Hgd tm1d MxCre +ve were injected with PBS (wildtype 694 
controls, n=5). Hgd tm1d MxCre +ve mice were injected with pIpC (MxCre +ve, n=15). B 695 
and C show relative HGD mRNA (HGD2 primers; relative to 18S) in the liver and kidney 696 
respectively, of MxCre +ve mice at 9, 15 and 20 weeks after the first injection, and in AKU 697 
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and wildtype controls at 20 weeks. Liver HGD mRNA was reduced, compared to wildtype 698 
controls, in MxCre +ve mice at 9 weeks and was sustained until 20 weeks. Kidney expression 699 
was not reduced by pIpC injection in MxCre +ve mice. D and E show plasma and urine HGA 700 
levels respectively, pre-injection, and at 2, 9, 15 and 20 weeks post-injection. Pre-injection, 701 
plasma HGA is not detected in MxCre +ve or WT mice and AKU mice showed elevated 702 
HGA. Post-pIpC, plasma HGA in MxCre +ve mice was increased at 2 weeks and remained at 703 
this level until 20 weeks. Pre-injection, urinary HGA is low in MxCre +ve and WT mice 704 
compared with AKU controls. Post-pIpC, urinary HGA showed a relatively small increase in 705 
MxCre +ve mice compared with AKU controls. The total number of pigmented chondrons in 706 
a representative section of the knee joint, stained with Schmorl’s, is shown in F, at 9, 15 and 707 
20 weeks post-injection.  708 
Accepted 07/09/2019; Human Molecular Genetics; Author Version 
36 
 
 709 
Figure 6. Liver-specific HGD knockout, induced by decreasing doses of pIpC, in Hgd tm1d 710 
MxCre +ve mice. A, shows the timescale of blood and urine sampling and injections of pIpC. 711 
B and C show relative HGD expression (HGD2 primers; relative to 18S) in Hgd tm1a -/- 712 
(AKU controls, n=4), Hgd tm1d MxCre WT (wildtype controls, n=7) and Hgd tm1d MxCre 713 
+ve mice (3.33µg/g, n=3; 0.1µg/g, n=3; 0.33µg/g, n=3; 0.1µg/g, n=5; 0.03µg/g, n=3; 714 
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0.01µg/g, n=3) in the liver and kidney respectively, 15 days post-pIpC. Varying the dose of 715 
pIpC resulted in a range of liver HGD expression in the MxCre +ve mice, with lower doses 716 
resulting in higher HGD expression. Kidney HGD expression was unchanged by pIpC. D and 717 
E show plasma and urine HGA, respectively, 15 days post-pIpC. A dose response in HGA 718 
was observed in both the plasma and the urine of MxCre +ve mice, with higher pIpC doses 719 
resulting in more elevated HGA. HGA was elevated in Hgd tm1a -/- and was low in wildtype 720 
controls. F and G show the relationship between liver HGD mRNA (expressed as a 721 
percentage of the mean wildtype level) with plasma and urinary HGA respectively, 15 days 722 
post-pIpC. 723 
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 724 
Figure 7. LC-QTOF-MS plasma flux analysis data acquired following injection of Hgd tm1a 725 
-/- and Hgd tm1a -/+ mice with 13C6-HGA. Plots show extracted ion chromatograms 726 
(theoretical accurate mass ±5 ppm) for 13C6-HGA and 
13C6-fumarylacetoacetic acid 727 
(FAA)/13C6-maleylacetoacetic acid (MAA). Traces are for individual plasma samples taken 728 
2-60 minutes post-injection and colour-coded to represent individual mice. 13C6-HGA was 729 
detected in Hgd tm1a -/- and Hgd tm1a -/+ indicating presence of the tracer. 13C6-MAA/FAA 730 
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was observed at 2-60 minutes post-injection in Hgd tm1a -/+, and was not observed in Hgd 731 
tm1a -/- at any time point. 732 
 733 
Abbreviations: AKU, alkaptonuria; ENU, N-ethyl-N-nitrosourea; FAA, fumarylacetoacetic 734 
acid; FAH, fumarylacetoacetate hydroxylase; HT-1, hereditary tyrosinaemia type I; HGA, 735 
homogentisic acid; HGD, homogentisate 1,2-dioxygenase; HPLC, high performance liquid 736 
chromatography; HPPD, 4-hydroxyphenylpyruvate dioxygenase; MAA, maleylacetoacetic 737 
acid; NTBC, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; PCT; proximal 738 
convoluted tubule; pIpC, polyinosinic:polycytidylic acid. 739 
 740 
